A study to confirm the efficacy of oral interferon in the treatment of chronic cough will be launched in January at a major Texas university. This Phase II, double-blind, placebo-controlled trial of 40 chronic obstructive pulmonary disease patients is expected to be completed in mid 2008.
Joseph Cummins, president and CEO of Amarillo Biosciences, said: “Because of the size of the chronic cough market, this is the most important patent application that the company has ever submitted to the US Patent Office.”